125 related articles for article (PubMed ID: 36112736)
1. Blood-brain barrier permeable benzylpiperidin-4-yl-linked benzylamino benzamides as dual cholinesterase inhibitors.
Banoo R; Nuthakki VK; Abdullaha M; Sharma M; Bharate SB
Drug Dev Res; 2022 Dec; 83(8):1791-1802. PubMed ID: 36112736
[TBL] [Abstract][Full Text] [Related]
2. Discovery of methoxy-naphthyl linked N-(1-benzylpiperidine) benzamide as a blood-brain permeable dual inhibitor of acetylcholinesterase and butyrylcholinesterase.
Abdullaha M; Nuthakki VK; Bharate SB
Eur J Med Chem; 2020 Dec; 207():112761. PubMed ID: 32942070
[TBL] [Abstract][Full Text] [Related]
3. Identification of aplysinopsin as a blood-brain barrier permeable scaffold for anti-cholinesterase and anti-BACE-1 activity.
Nuthakki VK; Yadav Bheemanaboina RR; Bharate SB
Bioorg Chem; 2021 Feb; 107():104568. PubMed ID: 33418314
[TBL] [Abstract][Full Text] [Related]
4. A Coumarin-Donepezil Hybrid as a Blood-Brain Barrier Permeable Dual Cholinesterase Inhibitor: Isolation, Synthetic Modifications, and Biological Evaluation of Natural Coumarins.
Sharma A; Nuthakki VK; Gairola S; Singh B; Bharate SB
ChemMedChem; 2022 Sep; 17(18):e202200300. PubMed ID: 35892288
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and structure-activity relationship of caffeine-based triazoles as dual AChE and BACE-1 inhibitors.
Sharma M; Sharma A; Nuthakki VK; Bhatt S; Nandi U; Bharate SB
Drug Dev Res; 2022 Dec; 83(8):1803-1821. PubMed ID: 36161804
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of β-site amyloid precursor protein cleaving enzyme 1 and cholinesterases by pterosins via a specific structure-activity relationship with a strong BBB permeability.
Jannat S; Balupuri A; Ali MY; Hong SS; Choi CW; Choi YH; Ku JM; Kim WJ; Leem JY; Kim JE; Shrestha AC; Ham HN; Lee KH; Kim DM; Kang NS; Park GH
Exp Mol Med; 2019 Feb; 51(2):1-18. PubMed ID: 30755593
[TBL] [Abstract][Full Text] [Related]
7. Design and Synthesis of Novel Dual Cholinesterase Inhibitors: In Vitro Inhibition Studies Supported with Molecular Docking.
Koca M; Güller U; Güller P; Dağalan Z; Nişancı B
Chem Biodivers; 2022 Jun; 19(6):e202200015. PubMed ID: 35470963
[TBL] [Abstract][Full Text] [Related]
8. Bis-Amiridines as Acetylcholinesterase and Butyrylcholinesterase Inhibitors:
Makhaeva GF; Kovaleva NV; Boltneva NP; Rudakova EV; Lushchekina SV; Astakhova TY; Serkov IV; Proshin AN; Radchenko EV; Palyulin VA; Korabecny J; Soukup O; Bachurin SO; Richardson RJ
Molecules; 2022 Feb; 27(3):. PubMed ID: 35164325
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and Biological Evaluation of New Cholinesterase Inhibitors for Alzheimer's Disease.
Hussein W; Sağlık BN; Levent S; Korkut B; Ilgın S; Özkay Y; Kaplancıklı ZA
Molecules; 2018 Aug; 23(8):. PubMed ID: 30110946
[TBL] [Abstract][Full Text] [Related]
10. Multitargeted C9-substituted ester and ether derivatives of berberrubine for Alzheimer's disease: Design, synthesis, biological evaluation, metabolic stability, and pharmacokinetics.
Raghuvanshi R; Jamwal A; Nandi U; Bharate SB
Drug Dev Res; 2023 Feb; 84(1):121-140. PubMed ID: 36461610
[TBL] [Abstract][Full Text] [Related]
11. Further SAR studies on natural template based neuroprotective molecules for the treatment of Alzheimer's disease.
Singh YP; Shankar G; Jahan S; Singh G; Kumar N; Barik A; Upadhyay P; Singh L; Kamble K; Singh GK; Tiwari S; Garg P; Gupta S; Modi G
Bioorg Med Chem; 2021 Sep; 46():116385. PubMed ID: 34481338
[TBL] [Abstract][Full Text] [Related]
12. Methoxy-naphthyl-Linked
Abdullaha M; Banoo R; Nuthakki VK; Sharma M; Kaur S; Thakur S; Kumar A; Jadhav HR; Bharate SB
ACS Omega; 2023 May; 8(20):17591-17608. PubMed ID: 37251153
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore-based drug design of AChE and BChE dual inhibitors as potential anti-Alzheimer's disease agents.
Gao H; Jiang Y; Zhan J; Sun Y
Bioorg Chem; 2021 Sep; 114():105149. PubMed ID: 34252860
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, in vitro assay, and molecular modeling of new piperidine derivatives having dual inhibitory potency against acetylcholinesterase and Abeta1-42 aggregation for Alzheimer's disease therapeutics.
Kwon YE; Park JY; No KT; Shin JH; Lee SK; Eun JS; Yang JH; Shin TY; Kim DK; Chae BS; Leem JY; Kim KH
Bioorg Med Chem; 2007 Oct; 15(20):6596-607. PubMed ID: 17681794
[TBL] [Abstract][Full Text] [Related]
15. Design, Synthesis, and Pharmacological Evaluation of Embelin-Aryl/alkyl Amine Hybrids as Orally Bioavailable Blood-Brain Barrier Permeable Multitargeted Agents with Therapeutic Potential in Alzheimer's Disease: Discovery of SB-1448.
Nuthakki VK; Choudhary S; Reddy CN; Bhatt S; Jamwal A; Jotshi A; Raghuvanshi R; Sharma A; Thakur S; Jadhav HR; Bharate SS; Nandi U; Kumar A; Bharate SB
ACS Chem Neurosci; 2023 Mar; 14(6):1193-1219. PubMed ID: 36812360
[TBL] [Abstract][Full Text] [Related]
16. Kinetics and molecular docking studies of loganin, morroniside and 7-O-galloyl-D-sedoheptulose derived from Corni fructus as cholinesterase and β-secretase 1 inhibitors.
Bhakta HK; Park CH; Yokozawa T; Min BS; Jung HA; Choi JS
Arch Pharm Res; 2016 Jun; 39(6):794-805. PubMed ID: 27106028
[TBL] [Abstract][Full Text] [Related]
17. Acetamide Derivatives of Chromen-2-ones as Potent Cholinesterase Inhibitors.
Prasad S; Kumar B; Kumar S; Chand K; Kamble SS; Gautam HK; Sharma SK
Arch Pharm (Weinheim); 2017 Aug; 350(8):. PubMed ID: 28699213
[TBL] [Abstract][Full Text] [Related]
18. Kinetics and molecular docking of dihydroxanthyletin-type coumarins from Angelica decursiva that inhibit cholinesterase and BACE1.
Ali MY; Seong SH; Jung HA; Jannat S; Choi JS
Arch Pharm Res; 2018 Jul; 41(7):753-764. PubMed ID: 30047040
[TBL] [Abstract][Full Text] [Related]
19. Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment.
Adeowo FY; Oyetunji TP; Ejalonibu MA; Ndagi U; Kumalo HM; Lawal MM
Chem Biodivers; 2021 Nov; 18(11):e2100361. PubMed ID: 34547176
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological activity of novel donepezil derivatives bearing N-benzyl pyridinium moiety as potent and dual binding site acetylcholinesterase inhibitors.
Lan JS; Zhang T; Liu Y; Yang J; Xie SS; Liu J; Miao ZY; Ding Y
Eur J Med Chem; 2017 Jun; 133():184-196. PubMed ID: 28388521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
